Антагонисты кальция в клинической практике: путь от критики до полного триумфа
Антагонисты кальция в клинической практике: путь от критики до полного триумфа
Небиеридзе Д.В. Антагонисты кальция в клинической практике: путь от критики до полного триумфа. Consilium Medicum. 2008; 10 (11): 14–18.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Список литературы
1. Report of the Holland Interuniversity Nifedipine/Metoprolol Trial (HINT) Research Group. Early treatment of unstable angina in the coronary care unit: a randomised double–blind placebo–controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both. Br Heart J 1986; 56: 400–13.
2. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose–related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326–31.
3. Hansson L, Lindholm L, Ekbom T et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular morbidity and mortality. The Swedish Trial in Old Patients with Hypertension-II Study. Lancet 1999; 354: 1751–6.
4. Staessen J, Ji-Guang Wang, Thijs L. Calcium–channel blockade and cardiovascular prognosis: recent evidence from clinical outcome trials. Am J Hypertens 2002; 15: 85S–93S.
5. Staessen JA, Fagard R, Thijs L et al., for the Systolic Hypertension in Europe Trial Investigators. Randomised double–blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757–64.
6. Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifediine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366–72.
7. Guidelines Committee. 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertension 2003; 21: 1011–53.
8. Исследование ЕНСОRE. Eur Heart J 1999; 1 Suppl M: M27–32; Circulation 2003 Jan 28; 107 (3): 422–8.
9. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. Lubsen J, Wagener G, Kirwan BA, de Brouwer S, Poole-Wilson PA; ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators. J Hypertens 2005; 23 (3): 641–8.
10. 2007 Guidelines for the management of Arterial hypertension. J Hypertens 2007; 25: 1105–87.
11. Elliot WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 210–7.
2. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose–related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326–31.
3. Hansson L, Lindholm L, Ekbom T et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular morbidity and mortality. The Swedish Trial in Old Patients with Hypertension-II Study. Lancet 1999; 354: 1751–6.
4. Staessen J, Ji-Guang Wang, Thijs L. Calcium–channel blockade and cardiovascular prognosis: recent evidence from clinical outcome trials. Am J Hypertens 2002; 15: 85S–93S.
5. Staessen JA, Fagard R, Thijs L et al., for the Systolic Hypertension in Europe Trial Investigators. Randomised double–blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757–64.
6. Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifediine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366–72.
7. Guidelines Committee. 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertension 2003; 21: 1011–53.
8. Исследование ЕНСОRE. Eur Heart J 1999; 1 Suppl M: M27–32; Circulation 2003 Jan 28; 107 (3): 422–8.
9. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. Lubsen J, Wagener G, Kirwan BA, de Brouwer S, Poole-Wilson PA; ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators. J Hypertens 2005; 23 (3): 641–8.
10. 2007 Guidelines for the management of Arterial hypertension. J Hypertens 2007; 25: 1105–87.
11. Elliot WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 210–7.
Авторы
Д.В.Небиеридзе
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.